Integril 0.75 mg/ml is an intravenous antiplatelet medication containing Eptifibatide, a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor. It is primarily indicated for patients with acute coronary syndrome (ACS), including unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI), as well as for patients undergoing percutaneous coronary intervention (PCI), including intracoronary stenting. Integril works by preventing platelet aggregation, reducing the risk of thrombus formation, and improving outcomes in high-risk cardiac patients.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Anti-platelet drugs

Pharmacology

Integril 0.75 mg/ml is a cyclic heptapeptide composed of six amino acids and one mercaptopropionyl (des-amino cysteinyl) residue. It selectively binds to the GP IIb/IIIa receptors on human platelets and reversibly inhibits platelet aggregation. By preventing fibrinogen, von Willebrand factor, and other adhesive ligands from binding to GP IIb/IIIa, Integril effectively blocks the final common pathway of platelet aggregation, reducing thrombus formation and supporting coronary blood flow during ACS or PCI.

Indications

Integril 0.75 mg/ml is indicated for:

• Patients with acute coronary syndrome (unstable angina/NSTEMI) who are managed medically or undergoing PCI

• Patients undergoing percutaneous coronary intervention, including intracoronary stenting

Dosage and Administration

Acute Coronary Syndrome (ACS):

• Normal renal function: 180 μg/kg IV bolus immediately after diagnosis, followed by continuous infusion at 2 μg/kg/min

• Creatinine clearance < 50 ml/min: Continuous infusion at 1 μg/kg/min

• Continue infusion until hospital discharge or initiation of coronary artery bypass graft (CABG) surgery, up to 72 hours

• For patients undergoing PCI, continue infusion for 18–24 hours post-procedure, with a minimum of 12 hours

Percutaneous Coronary Intervention (PCI):

• Normal renal function: 180 μg/kg IV bolus immediately before PCI, followed by continuous infusion at 2 μg/kg/min and a second 180 μg/kg bolus 10 minutes later

• Creatinine clearance < 50 ml/min: Continuous infusion at 1 μg/kg/min with a second bolus

• Discontinue infusion prior to CABG surgery

Administration Notes:

• Inspect solution visually for particulate matter and discoloration

• Compatible with IV lines containing saline, dextrose, or certain medications (alteplase, heparin, morphine, nitroglycerin, etc.)

• Do not administer with furosemide in the same line

Drug Interactions

• Concomitant use with other antiplatelets, anticoagulants, NSAIDs, thrombolytics, or dipyridamole may increase bleeding risk

• Avoid combining with other GP IIb/IIIa inhibitors

• Enoxaparin does not affect Integril pharmacokinetics

Contraindications

• Active or recent abnormal bleeding (within 30 days)

• History of bleeding disorders

• Severe uncontrolled hypertension (systolic >200 mmHg or diastolic >110 mmHg)

• Hypersensitivity to Eptifibatide or any component

Side Effects

• Most common: Bleeding

• Other possible adverse effects: intracranial hemorrhage, stroke, thrombocytopenia, allergic reactions, hypotension

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Pregnancy and Lactation

• Pregnancy: Category B; animal studies show no fetal harm, but human studies are limited

• Lactation: Unknown if excreted in human milk; use caution

Overdose

Limited experience; potential effects include hemorrhage, hypotension, and thrombocytopenia. Integril is not extensively bound to plasma proteins and may be cleared via dialysis.

Pediatric Use

Safety and efficacy in children have not been established.

Storage Conditions

• Store refrigerated at 2–8°C

• May be kept at room temperature for up to 2 months

• Protect from light and discard unused portions

Mode of Action

Integril 0.75 mg/ml reversibly inhibits platelet aggregation by binding to GP IIb/IIIa receptors and preventing fibrinogen and von Willebrand factor from cross-linking platelets. This reduces thrombus formation and helps maintain coronary blood flow in patients with ACS or undergoing PCI.